Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

被引：24
|
作者：
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacquiline
Powles, Thomas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
284
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.
    Sonpavde, Guru P.
    Galsky, Matt D.
    Wright, Phoebe
    Hepp, Zsolt
    Chang, Nancy N.
    Willmon, Candice
    Sesterhenn, Steven
    Liu, Yutong
    Morgans, Alicia K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
    Lin, Chang-Ting
    Su, Po-Jung
    Huang, Shih-Yu
    Wu, Chia-Che
    Wang, Hung-Jen
    Cheng, Yuan-Tso
    Luo, Hao-Lun
    Chen, Chien-Hsu
    Liu, Ting-Ting
    Huang, Chun-Chieh
    Su, Yu-Li
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (09) : 407 - 414
  • [43] First-line pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
    Qin, S.
    Liang, T.
    Gu, S.
    Gou, H.
    Peng, C.
    Pan, Y.
    Song, T.
    Su, H.
    Cao, K.
    Liang, H.
    Ying, J.
    Geng, Z.
    Yu, W.
    Zhao, H.
    Bai, Y.
    Hao, C-Y.
    Wang, W.
    Li, N.
    Malhotra, U.
    Ren, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S230 - S230
  • [44] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [45] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [46] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)
    Balar, A., V
    Galsky, M. D.
    Rosenberg, J. E.
    LANCET, 2017, 390 (10097): : 848 - 848
  • [47] First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
    Soll, Dominik
    Bischoff, Philip
    Frisch, Anne
    Jensen, Marie
    Karadeniz, Zehra
    Mogl, Martina T.
    Horst, David
    Penzkofer, Tobias
    Spranger, Joachim
    Keilholz, Ulrich
    Mai, Knut
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [48] Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Van Cutsem, Eric
    Wang, Jiang Dian
    Lam, Baohoang
    Dalal, Rita
    Koshiji, Minori
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study
    Dorte Nielsen
    Per Dombernowsky
    Susanne Kornum Larsen
    Ole Paaske Hansen
    Torben Skovsgaard
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 459 - 466
  • [50] Vinflunine maintenance treatment following first-line therapy of advanced urothelial carcinoma - results from the JASiMA trial
    De Wit, M.
    De Geeter, P.
    Galli, L.
    Hegele, A.
    Schrader, M.
    Schenck, M.
    Dorp, F. Vom
    Bolten, M.
    Fahlenkamp, D.
    Hampel, C.
    Krause, S.
    Riggi, M.
    Fougeray, R.
    De Almeida, C.
    Edlich, B.
    Pichler, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S527 - S527
12345